Ozempic

The brand name for semaglutide 0.5 mg, 1 mg, and 2 mg weekly subcutaneous injection, approved by the FDA for type 2 diabetes management. Manufactured by Novo Nordisk. SUSTAIN clinical trial program demonstrated HbA1c reductions of 1.5–1.8% and weight loss of 4–6 kg. Became widely discussed for off-label weight loss use due to its efficacy, driving prescription demand that created supply shortages in 2022–2023. The 2.4 mg obesity-specific formulation is marketed separately as Wegovy.